ArticleWorld journal of surgical oncology2025
Survival outcomes and prognostic impact of adjuvant chemotherapy in stage IB lung adenocarcinoma with cribriform component.
Article in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundCribriform morphology is a distinct high-grade pattern associated with aggressive tumor biology and poor survival outcomes in lung adenocarcinoma (LUAD). The potential survival benefits of adjuvant chemotherapy (ACT) for stage IB LUAD containing cribriform components remain undefined. This study aims to investigate the prognostic significance of ACT in patients with stage IB LUAD containing cribriform components.
methodsThis retrospective study enrolled 235 surgically resected LUAD patients with pathologically confirmed stage IB disease from Qilu Hospital of Shandong University. To mitigate selection bias, propensity score matching (PSM) was implemented with 1:1 nearest-neighbor matching. Survival outcomes were compared using Kaplan-Meier methodology with log-rank testing for intergroup comparisons. Univariate and Multivariate Cox proportional hazards models were constructed to identify independent prognostic factors.
resultsPatients were stratified into cribriform-positive and cribriform-negative cohorts based on histologically confirmed cribriform component status, resulting in 67 patients with cribriform components and 168 patients without this histopathological feature. After PSM, 59 pairs of patients were finally included for analysis. The results showed that both the 5-year overall survival (OS) rates (63.5% vs. 84.5%, P = 0.013) and 5-year recurrence-free survival (RFS) rates (58.7% vs. 77.7%, P = 0.033) for cribriform-positive patients were lower than those for cribriform-negative patients. In addition, we further explored whether patients with cribriform components could derive a survival benefit from postoperative ACT. The results indicated that patients receiving ACT demonstrated a significant improvement in 5-year rates of RFS compared to observation-only management (70.2% vs. 38.6%, P = 0.0096). Univariate and multivariate Cox proportional hazards regression analyses identified the resection range (HR = 0.197; 95% CI: 0.061-0.632; P = 0.006), STAS (HR = 2.653; 95% CI: 1.131-6.221; P = 0.025), and ACT (HR = 0.334; 95% CI: 0.151-0.742; P = 0.007) as independent prognostic factors for RFS.
conclusionThe presence of cribriform components in stage IB LUAD was associated with diminished survival prognosis. Patients with stage IB LUAD containing cribriform components could derive survival benefit from postoperative ACT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.